Inovio Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$1.61

−0.56%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:58 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.62
Volume: 98,904
Day's high: —
Day's low: —

In brief

Inovio Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $167M.
Its shares closed at $1.62 on 4 Nov 2026, down 33.3% over the past year.
From India you can buy INO in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Inovio Pharmaceuticals, Inc. (INO) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole INO share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade INO options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +43.4% (SPY −1.6%, XLV +13.5%). 3 months: +139.3% (SPY −0.4%, XLV +15.5%). 1 year: −33.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: INO, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $1.62 was 38.7% above its 50-day average ($1.17) and 28.0% above its 200-day average ($1.27). It has closed above the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed below the 200-day on 14 Jan 2026, 203 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
6.9 days to cover short interest
21.3M shares were sold short at the 15 Oct 2026 settlement, 20.6% of the 103.4M shares outstanding; covering them would take 6.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
48% of the way up its 52-week range
Closed at $1.62 on 4 Nov 2026: 40.4% below the 52-week high of $2.72 (17 Dec 2025) and 171.8% above the low of $0.60 (30 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+43.4%

6 months+30.6%

1 year−33.3%

5 years−98.1%

Newswire

About

Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.

Website

Notable moves

November 2, 2026
+213.75%
December 13, 2024
−38.30%
October 10, 2023
+41.00%

Newswire

About

Website

Notable moves

November 2, 2026
+213.75%
December 13, 2024
−38.30%
October 10, 2023
+41.00%

Inovio Pharmaceuticals, Inc.

XNASHealth care

Last traded price · USD

$1.61

−0.56%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:58 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $1.62
Volume: 98,904
Day's high: —
Day's low: —

In brief

Inovio Pharmaceuticals, Inc. is a health care company listed on Nasdaq, valued at about $167M.
Its shares closed at $1.62 on 4 Nov 2026, down 33.3% over the past year.
From India you can buy INO in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Inovio Pharmaceuticals, Inc. (INO) shares from India?

Do I need the price of a whole INO share to invest?

How much can I invest in US stocks in a year?

Can I trade INO options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +43.4% (SPY −1.6%, XLV +13.5%). 3 months: +139.3% (SPY −0.4%, XLV +15.5%). 1 year: −33.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: INO, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $1.62 was 38.7% above its 50-day average ($1.17) and 28.0% above its 200-day average ($1.27). It has closed above the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed below the 200-day on 14 Jan 2026, 203 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
6.9 days to cover short interest
21.3M shares were sold short at the 15 Oct 2026 settlement, 20.6% of the 103.4M shares outstanding; covering them would take 6.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
48% of the way up its 52-week range
Closed at $1.62 on 4 Nov 2026: 40.4% below the 52-week high of $2.72 (17 Dec 2025) and 171.8% above the low of $0.60 (30 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+43.4%

6 months+30.6%

1 year−33.3%

5 years−98.1%

Newswire

About

Website

Notable moves

November 2, 2026
+213.75%
December 13, 2024
−38.30%
October 10, 2023
+41.00%

Newswire

About

Website

Notable moves

November 2, 2026
+213.75%
December 13, 2024
−38.30%
October 10, 2023
+41.00%

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

6.9 days to cover short interest

48% of the way up its 52-week range

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

6.9 days to cover short interest

48% of the way up its 52-week range